Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Saturday, Zacks.com reports.
According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
KPTI has been the topic of several other reports. Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Monday, July 8th. Robert W. Baird reaffirmed an “outperform” rating and issued a $25.00 target price (up from $15.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. BidaskClub raised shares of Zumiez from a “sell” rating to a “hold” rating in a research note on Saturday, June 22nd. ValuEngine raised shares of Zillow Group from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $48.00 price objective (down from $52.00) on shares of CELYAD SA/ADR in a research report on Friday, July 5th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $17.41.
Shares of NASDAQ KPTI opened at $8.03 on Friday. The company has a current ratio of 6.19, a quick ratio of 6.19 and a debt-to-equity ratio of 0.98. Karyopharm Therapeutics has a 52 week low of $3.92 and a 52 week high of $21.71. The business has a fifty day moving average price of $6.37. The stock has a market capitalization of $488.74 million, a P/E ratio of -2.56 and a beta of 2.43.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, May 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%. The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.75 million. As a group, equities analysts predict that Karyopharm Therapeutics will post -3.79 EPS for the current year.
Several hedge funds have recently made changes to their positions in KPTI. PNC Financial Services Group Inc. boosted its holdings in shares of Karyopharm Therapeutics by 660.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock valued at $36,000 after buying an additional 3,300 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Karyopharm Therapeutics by 169,300.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock worth $59,000 after purchasing an additional 10,158 shares in the last quarter. Legal & General Group Plc boosted its stake in Karyopharm Therapeutics by 31.3% in the 4th quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock worth $95,000 after purchasing an additional 2,411 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Karyopharm Therapeutics by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $152,000 after purchasing an additional 12,711 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC boosted its stake in Karyopharm Therapeutics by 24.4% in the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 25,000 shares of the company’s stock worth $234,000 after purchasing an additional 4,905 shares in the last quarter. Hedge funds and other institutional investors own 84.20% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Read More: Do equity income investments outperform growth and income investments?
Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.